Rezultati pretraživanja
  1. A prognostic biomarker developed using deep learning with H&E sections stratified patients with stage II or III CRC into sufficiently distinct prognostic groups that potentially could be used to guide selection of adjuvant treatment:

  2. Patients with metastatic colorectal cancer treated with the combination of onvansertib plus FOLFIRI had a 100% clinical benefit rate at 8 weeks by radiographic response.

  3. Steep Increase Seen in Incidence of CRC From Age 49 to 50 Years

  4. On 💡we really need to support more & engage in 🧬biomarker driven . Advances for many of these cancers is coming for subsets. Cancers are heterogeneous👇🏼. One size fits all approach less likely to be successful.

  5. 4. velj

    It is hard for me to understand such result cetuximab in with resectable liver metastasis (New EPOC) do worse: long-term results ⁦

  6. Last day for taking this survey on CIPN is tomorrow. Your opportunity to influence decision-making about CIPN. Very simple process and very small survey. Don't forget to do this..

  7. 4. velj

    Also it is 71 degrees here in San Antonio and we are hiring 🙂☺😉

  8. 3. velj

    Dr. Lenz “The incredible complete response rates & overall response rates seen are never seen with chemotherapy, & it’s very well tolerated, so if I have a choice, I would start with nivolumab-ipilimumab in 1st-line -H...” from ASCO

  9. 3. velj

    Colorectal cancer survival outcomes better for private hospital patients (in South Australia). ... this would appear to support earlier study from Victoria. ⁦

  10. 3. velj

    Circulating Epigenetic Biomarkers for Detection of Recurrent

  11. 2. velj

    (EPOC): more is not always better. Cetuximab in the preoperative setting is a disadvantageous to survival. The question is why?

  12. 2. velj
  13. 1. velj

    CARDS FOR JAYDEN! This 11-year-old boy is facing colon cancer. He will have surgery Feb. 11 at UNC Children’s. Send cards to Jayden Oakes, C/O Joe Bullock, 55 Bullock Lane, Durham, N.C. 27713 Let Jayden know we support him!

  14. Thanks for the discussion..We have some pts withChek2 germ-line mutations in @COLONTOWN

  15. Patient question: Why do lung mets respond "better" than liver mets? Inflammatory/repair mechanisms different between the 2 organs? Drugs need to be metabolized in the liver, so liver taxed extra? What is the reason? Could someone break it down? Thank you!

  16. 31. sij
  17. 31. sij

    Congrats Colorado advocates, what a mile-high win! (Sorry, couldn’t resist.)

  18. Odgovor korisniku/ci

    When will the OS data be available? As someone who had 3m Capox for Stage 3b Rectal cancer, I am curious..

  19. 31. sij

    very patient friendly paper re NTRK fusion treatment in . Now, the question, is... where do we find them... MSI or immunotherapy groups, best guess.

  20. 31. sij

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.